2Henderson C,Berry DA,Demetri GD,et a1.Improved outcomes from adding sequential paelitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[J].J Clin Oncol,2003,21(6):976-983.
3Steven D Heys,Tarun Sarkar,Andrew W Hutcheon,et al.Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer[J].Expert Opinion on Pharmacotherapy,2004,5(10):2147-2157.
4Citron ML,Berry DA,Cirrineione C,et a1.Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer:first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 974l[J].J Clin Oncol,2003,21(8):1431-1439.
7Early Breast Cancer Trialists' Collaborative Group.Tamoxifen for early breast cancer:an overview of the randomized trials[C].Lancet,1998,351:1451.
8Coombes RC,Hall E,Gibson LJ,et al.A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer[J].N Engl J Med,2004,350:1081.
9Baum M,Buzdar AU,Cuzik J,et al.Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer:first results of the ATAC randomised trial[J].Lancet,2002,359:2131.
10Goss PE,Ingle JN,Martino S,et al.A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer[J].N Engl J Med,2003,349:1793.
7[2]Nahboltz J M, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol,2000, 18 (22) :3758
8[3]Bonneterre J, Thurliman B, Robertson J F R, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol, 2000, 18 (22) :3748
9[5]Patrick Therasse, Susan G, Arbuck, et al. New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Insitute, 2000, 92 (3) : 205
10[8]Buzdar A, Jonat W, Howell A, et al. Significant improved survival with arimidex (anastrozole) vs megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase trials. J Clin Oncol, 1996, 14:2000
